Current treatment of AL amyloidosis
- 30 July 2009
- journal article
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 94 (8), 1044-1048
- https://doi.org/10.3324/haematol.2009.008912
Abstract
Several effective chemotherapy regimens have been developed during the last decade significantly improving the outlook of patients with AL amyloidosis. Drs. Palladini and Merlini describe our current knowledge in the field and examine future perspectives. See related article on page 1094.Keywords
This publication has 41 references indexed in Scilit:
- Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantationBlood, 2007
- Effect of hematologic response on outcome of patients undergoing transplantation for primary amyloidosis: importance of achieving a complete responseHaematologica, 2007
- Risk‐adapted autologous stem cell transplantation with adjuvant dexamethasone ± thalidomide for systemic light‐chain amyloidosis: results of a phase II trialBritish Journal of Haematology, 2007
- High-Dose Melphalan versus Melphalan plus Dexamethasone for AL AmyloidosisNew England Journal of Medicine, 2007
- Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosisBlood, 2007
- The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosisBlood, 2006
- Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosisBlood, 2006
- Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trialBlood, 2006
- High-Dose Therapy and Autologous Hematopoietic Stem Cell Transplantation for Patients With Primary Systemic Amyloidosis: A Center for International Blood and Marrow Transplant Research StudyMayo Clinic Proceedings, 2006
- Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in ALBlood, 2006